Monitor the company's cash burn rate and upcoming pipeline catalysts (e.g., data readouts for bitopertin or DISC-0974) as the extended loan runway provides capital into 2028. The $30M draw signals active capital deployment, likely funding ongoing clinical trials. No pricing of Tranches 2/3 was disclosed, so the total potential debt is capped at an unknown amount.
IRON drugs
IRON drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 1 $74.95entry
- T+1 · 5mo ago +1.75%α +1.88% · $76.26
- T+5 · 4mo ago +6.42%α +6.16% · $79.76
- T+20 · 4mo ago −1.71%α +0.48% · $73.67
- T+60 · 8w ago −11.35%α −14.23% · $66.44
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Disc Medicine amended its existing loan agreement with Hercules Capital, drawing $30M from Tranche 1-B and restructuring the remaining $50M Tranche 1-C into two $25M tranches. The amendment also extends draw periods for Tranches 2 and 3 to late 2027/2028 and defers the minimum cash covenant test to July 2028, providing extended financial flexibility for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Disc Medicine drew $30M under Tranche 1-B of the Hercules Capital loan agreement.
- The existing $50M Tranche 1-C was split into a $25M tranche available through March 31, 2027, and a $25M Tranche 1-D available through April 30, 2027.
- Draw periods for Tranche 2 and Tranche 3 advances were extended to December 15, 2027 and June 30, 2028, respectively.
- Minimum cash covenant initial testing date was deferred to July 1, 2028.
- No financial data (revenue, earnings, cash balance) was reported in the filing; figures are not available for analysis.
Financial Impact
Drew $30M of existing debt capacity; total available future draws up to $75M across three tranches ($25M Tranche 1-C, $25M Tranche 1-D, plus Tranches 2 and 3 of undisclosed size). No revenue or earnings data in filing.
Risk Factors
- Increased debt burden from the $30M draw and potential future draws; interest and covenants apply.
- No product revenue; company remains pre-commercial with dependency on clinical-stage pipeline success.
- Additional draws or amendments could dilute equity if debt converts or forces equity-linked financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-290542 |
| Document: 0001193125-26-290542-index-headers.html | 0001193125-26-290542 |
| Document: 0001193125-26-290542-index.html | 0001193125-26-290542 |
| Document: 0001193125-26-290542.txt | 0001193125-26-290542 |
Track record
43 reports on IRON
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers